Skip to main content
. Author manuscript; available in PMC: 2007 Nov 15.
Published in final edited form as: Clin Cancer Res. 2006 Nov 15;12(22):6702–6708. doi: 10.1158/1078-0432.CCR-06-0635

Table 4.

HER2 overexpression in patient subgroups stratified by hormone receptor and BRMS1 status

Patient subgroup HER2 positive HER2 negative
ER (P = 0.001)
 ER+/BRMS1+ 9 of 145 (6%) 136 of 145 (94%)
 ER+/BRMS1− 7 of 42 (17%) 35 of 42 (83%)
 ER−/BRMS1+ 9 of 33 (27%) 24 of 33 (73%)
 ER−/BRMS1− 5 of 17 (29%) 12 of 17 (71%)
PR (P = 0.01)
 PR+/BRMS1+ 7 of 117 (6%) 110 of 117 (94%)
 PR+/BRMS1− 4 of 27 (15%) 23 of 27 (85%)
 PR−/BRMS1+ 11 of 61 (18%) 50 of 61 (82%)
 PR−/BRMS1− 8 of 32 (25%) 24 of 32 (75%)